Posted On:
July 29, 2010
Johnson & Johnson Settle For $75 Million
Johnson & Johnson has agreed to a $75 Million national settlement related to allegations that its subsidiary, Ortho-McNeil-Janssen Pharmaceuticals schemed to improperly market the drug Topamax for uses that were not approved by the Food & Drug Administration.
The Commonwealth of Kentucky’s share of the settlement is nearly $2 million.
